Cancer and Aging
Cancer cells exploit an aging “infrastructure” to threaten life in those 60 and older.
Progress Against Cancer
Cancer cells exploit an aging “infrastructure” to threaten life in those 60 and older.
The FDA granted accelerated approval to selpercatinib to treat solid tumors harboring RET gene fusions. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to selpercatinib (Retevmo) for the treatment of adult...
The FDA granted full approval to selpercatinib for the treatment of patients with advanced lung cancer. The U.S. Food and Drug Administration (FDA) has approved selpercatinib (Retevmo) for the treatment of patients with locally...
Researchers highlight need for outreach and educational programs to address survivorship disparities.
Researchers describe their efforts to understand and improve cancer screening and treatment among underserved populations.
AACR conference explores the science of cancer disparities and what needs to be done to improve cancer outcomes for all people.
Air pollution research provides clues to how cancer starts, and KRAS-targeting drug appears to keep cancer at bay longer than standard of care, but questions remain.
Get your hearing checked periodically if you will be undergoing chemotherapy with neurotoxic effects.
Early-onset cancer is increasing globally, testing population-wide preventive DNA testing, and more from the week in cancer news.
The immune checkpoint inhibitor durvalumab was approved in combination with chemotherapy for certain biliary tract cancers that have spread. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) in combination with the...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More